Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELOSEF '500' (Cephradine) is an oral first-generation cephalosporin antibiotic in capsule form, currently in pre-launch development by Teva. It is indicated for bacterial infections treatable by cephalosporin therapy. Cephradine works by inhibiting bacterial cell wall synthesis, making it bactericidal against susceptible gram-positive and gram-negative organisms.
Pre-Launch
This pre-launch product signals limited current commercial scale; career growth depends on successful market entry and competitive positioning in a mature antibiotic category.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on VELOSEF '500' at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.